

# World Journal of *Pharmacology*

*World J Pharmacol* 2016 June 9; 5(2): 51-58





## Editorial Board

2016-2019

The *World Journal of Pharmacology* Editorial Board consists of 455 members, representing a team of worldwide experts in pharmacology. They are from 42 countries, including Australia (13), Austria (3), Belarus (1), Belgium (3), Brazil (3), Bulgaria (1), Canada (12), Chile (2), China (46), Czech Republic (1), Denmark (2), Egypt (1), Finland (3), France (13), Germany (7), Greece (17), Hungary (6), Iceland (1), India (11), Iran (4), Ireland (1), Israel (12), Italy (39), Japan (30), Malaysia (1), Netherlands (10), New Zealand (2), Poland (3), Portugal (2), Russia (1), Saint Kitts and Nevis (1), Saudi Arabia (1), Serbia (1), Singapore (7), South Korea (9), Spain (22), Sweden (4), Switzerland (2), Thailand (1), Turkey (6), United Kingdom (19), and United States (131).

### EDITOR-IN-CHIEF

Geoffrey Burnstock, *London*

### ASSOCIATE EDITORS

Raouf A Khalil, *Boston*

Godefridus J Peters, *Amsterdam*

W.S. Fred WONG, *Singapore*

### GUEST EDITORIAL BOARD MEMBERS

Chia-Hsiang Chen, *Zhunan*

Jong-Yuh Cherng, *Chia-yi*

Jia-You Fang, *Taoyuan*

Ming-Fa Hsieh, *Chung Li*

Dong-Ming Huang, *Miaoli County*

Tsong-Long Hwang, *Taoyuan*

Jiiang-Huei Jeng, *Taipei*

Mei-Chuan Ko, *Taipei*

Po-Lin Kuo, *Kaohsiung*

Hsien-Yuan Lane, *Taichung City*

Chen-Lung Steve Lin, *Kaohsiung*

Min-Hsiung Pan, *Taipei*

Joan-Rong Sheu, *Taipei*

Chih-Hsin Tang, *Taichung*

Chin-Hsiao Tseng, *Taipei*

Chih-Shung Wong, *Taipei*

Sheng-Nan Wu, *Tainan City*

Wen-Bin Wu, *Taipei*

Chuen-Mao Yang, *Kwei-San*

### MEMBERS OF THE EDITORIAL BOARD



**Australia**

Jonathon C Arnold, *Sydney*

Alexander Bobik, *Melbourne*

Stephen J Clarke, *St Leonards*

Brian Dean, *Melbourne*

Xiao-Jun Du, *Melbourne*

Cherrie A Galletly, *Adelaide*

Jacob George, *Sydney*

Andrew J Lawrence, *Parkville*

Johnson Mak, *Victoria*

Des R Richardson, *Sydney*

Shaun L Sandow, *Sydney*

Karly C Sourris, *Melbourne*

Fanfan Zhou, *Sydney*



**Austria**

Andreas Bernkop-Schnurch, *Innsbruck*

Martin Hohenegger, *Vienna*

Siegfried Kasper, *Vienna*



**Belarus**

Peter Gregor Rytik, *Minsk*



**Belgium**

Van D Debby, *Antwerp*

Mark Van de Casteele, *Brussels*

Mathieu Vinken, *Brussels*



**Brazil**

Maria de Nazaré C Soeiro, *Rio de Janeiro*

Waldiceu A Verri Jr, *Londrina*

Angelina Zanesco, *Sao Paulo*



**Bulgaria**

Stanislav G Yanev, *Sofia*



**Canada**

Sylvain G Bourgoin, *Québec*

Subrata Chakrabarti, *London*

Thomas KH Chang, *Vancouver*

Janos G Filep, *Montreal*

Pierre A Guertin, *Quebec*

Suhayla Mukaddam-Daher, *Montréal*

Claude Rouillard, *Quebec*

Jean Sévigny, *Québec*

Ashok K Srivastava, *Montréal*

Margarey D Weiss, *Vancouver*

Jonathan P Wong, *Main Station*

Xi Yang, *Winnipeg*



**Chile**

Javier Palacios, *Iquique*

Armando Rojas Rubio, *Talca*



**China**

George G Chen, *Hong Kong*

Chi-Hin Cho, *Hong Kong*

Liwu Fu, *Guangzhou*

Qin He, *Chengdu*

Qing-Yu He, *Guangzhou*

Xi-Qun Jiang, *Nanjing*

Tai-Yi Jin, *Shanghai*

Yiu Wa Kwan, *Hong Kong*

Ke Lan, *Chengdu*  
 George Pak-Heng Leung, *Hong Kong*  
 Jian-Jun Li, *Beijing*  
 Zhi-Xiu Lin, *Hong Kong*  
 Xiao-Dong Liu, *Nanjing*  
 Xin-Yong Liu, *Jinan*  
 Liang Peng, *Shenyang*  
 Mei Qiang, *Taiyuan*  
 Yong-Yong Shi, *Shanghai*  
 Jing-Fang Wang, *Shanghai*  
 Yong-Qing Wang, *Nanjing*  
 Chi-Ming Wong, *Hong Kong*  
 William Ka Kei Wu, *Hong Kong*  
 Ruian Xu, *Xiamen*  
 Xiao-Qiang Yao, *Hong Kong*  
 Wei-Hai Ying, *Shanghai*  
 Shu-Biao Zhang, *Dalian*  
 Yu Zhang, *Beijing*



#### Czech Republic

Kamil Kuca, *Hradec Kralove*



#### Denmark

Morten Grunnet, *Ballerup*  
 Yasser A Mahmmoud, *Aarhus*



#### Egypt

Nagwa MN El-Din, *Alexandria*



#### Finland

Seppo Kahkonen, *Helsinki*  
 Hannu I Kankaanranta, *Seinajoki*  
 Helder A Santos, *Helsinki*



#### France

Eric Boue-Grabot, *Bordeaux*  
 Christian Bronner, *Illkirch*  
 Rene Bruno, *Marseille*  
 Marie-Chantal Canivenc-Lavier, *Dijon*  
 Bertrand Cariou, *Nantes*  
 Emmanuelle Corruble, *Le Kremlin Bicêtre*  
 Gerard, *Siest, Nancy*  
 Laurent Karila, *Villejuif*  
 Frederic Lagarce, *Angers*  
 Tanguy Maurice, *Montpellier*  
 Fernando Rodrigues-Lima, *Paris*  
 Jean-Marc Sabatier, *Rousset*  
 Steeve H Thany, *Angers*



#### Germany

Axel Becker, *Magdeburg*  
 Thomas Efferth, *Mainz*  
 Florian Lang, *Tuebingen*  
 Huige Li, *Mainz*  
 Frank Thevenod, *Witten*  
 Michael Wink, *Heidelberg*  
 Jianbo Xiao, *Würzburg*



#### Greece

Panagiotis G Anagnostis, *Thessaloniki*  
 Charalambos Antoniadis, *Athens*  
 Ekaterini Chatzaki, *Alexandroupolis*  
 Vassilis J Demopoulos, *Thessaloniki*  
 Moses S Elisaf, *Ioannina*  
 Panagiotis P Ferentinos, *Athens*  
 Dimitrios Galaris, *Ioannina*  
 Tzortzis Nomikos, *Athens*  
 Constantinos M Paleos, *Aghia Paraskevi*  
 George Panagis, *Rethymno*  
 Andreas Papapetropoulos, *Patras*  
 Kosmas I Paraskevas, *Athens*  
 George P Patrinos, *Patras*  
 Evangelos Rizos, *Ioannina*  
 Despina Sanoudou, *Athens*  
 Konstantinos N Syrigos, *Athens*  
 Ioannis S Vizirianakis, *Thessaloniki*



#### Hungary

Albert Császár, *Budapest*  
 Peter Hamar, *Budapest*  
 Peter Krajcsi, *Budaors*  
 Gabor Maksay, *Budapest*  
 Attila J Miseta, *Cserkut*  
 Joseph Molnar, *Szeged*



#### Iceland

Hekla Sigmundsdottir, *Reykjavik*



#### India

VN Balaji, *Bangalore*  
 Chiranjib Chakraborty, *Vellore*  
 Naibedya Chattopadhyay, *Lucknow*  
 Swaran JS Flora, *Gwalior*  
 Rumi Ghosh, *Mumbai*  
 Srinivas Gopala, *Thiruvananthapuram*  
 Seetharamappa Jaldappagari, *Dharwad*  
 Noboru Motohashi,   
 Basavaraj K Nanjwade, *Karnataka*  
 Kishore M Paknikar, *Pune*  
 Vikas Anand Saharan, *Uttarakhand*  
 Abdus Samad, *Mumbai*



#### Iran

Payman Adibi, *Isfahan*  
 Ahmad R Dehpour, *Tehran*  
 Mehrdad Hamidi, *Zanjan*  
 Arash Mowla, *Shiraz*



#### Ireland

Marek W Radomski, *Dublin*



#### Israel

Galila Agam, *Beer-Sheva*

Robert H Belmaker, *Beer Sheva*  
 Shomron Ben-Horin, *Tel-Hashomer*  
 Arik Dahan, *Beer-Sheva*  
 Hagit Eldar-Finkelman, *Rehovot*  
 Eliezer Flescher, *Tel Aviv*  
 Moshe Gavish, *Haifa*  
 Israel Hanukoglu, *Ariel*  
 Joseph Kost, *Beer-Shiva*  
 Irena Manov, *Haifa*  
 Mordechai Muszkat, *Jerusalem*  
 Michal Schwartz, *Rehovot*



#### Italy

Giuseppe Barbaro, *Rome*  
 Francesca Borrelli, *Napoli*  
 Franco Borsini, *Pomezia*  
 Silvio Caccia, *Milan*  
 Giuseppe M Campo, *Messina*  
 Raffaele Capasso, *Naples*  
 Mauro AM Carai, *Cagliari*  
 Dario Cattaneo, *Milan*  
 Davide Cervia, *Viterbo*  
 Giuseppe Cirino, *Napoli*  
 Emilio Clementi, *Milano*  
 Massimo Collino, *Torino*  
 Vincenzo Cuomo, *Rome*  
 Francesca Fallarino, *Perugia*  
 Tullio Florio, *Genova*  
 Vittorio Gentile, *Naples*  
 Guido Grassi, *Milan*  
 Mario Grassi, *Trieste*  
 Annalisa Guaragna, *Napoli*  
 Milena Gusella, *Trecenta*  
 Francesco Impagnatiello, *Milan*  
 Angelo A Izzo, *Naples*  
 Luca La Colla, *Parma*  
 Aurelio Leone, *Castelnuovo Magra*  
 Mauro Magnani, *Urbino*  
 Mario Marchi, *Genoa*  
 Silvia Marinelli, *Rome*  
 Robert Nistico, *Rome*  
 Francesco Parmeggiani, *Ferrara*  
 Sabina Passamonti, *Trieste*  
 Emilio Perucca, *Pavia*  
 Carlo Riccardi, *Perugia*  
 Graziano Riccioni, *Chieti*  
 Sergio Rutella, *Rome*  
 Gianni Sava, *Trieste*  
 Pier A Serra, *Sassari*  
 Luca Steardo, *Roma*  
 Claudiu T Supuran, *Florence*  
 Gianluca Tettamanti, *Varese*



#### Japan

Katsuya Dezaki, *Tochigi*  
 Jun Fang, *Kumamoto*  
 Takahisa Furuta, *Hamamatsu*  
 Mitsuko Furuya, *Yokohama*  
 Osamu Handa, *Kyoto*  
 Kenji Hashimoto, *Chiba*  
 Zhi-Qing Hu, *Tokyo*  
 Peng Huang, *Okayama*  
 Toru Kobayashi, *Niigata*  
 Hiroshi Kunugi, *Tokyo*  
 Makoto Makishima, *Itabashi-ku*

Makoto Makishima, *Tokyo*  
Takayuki Masaki, *Oita*  
Shin-Ichiro Miura, *Fukuoka*  
Yuji Naito, *Kyoto*  
Satomi Onoue, *Shizuoka*  
Honoo Satake, *Osaka*  
Masaharu Seno, *Okayama*  
Yasuyuki Shimada, *AKITA*  
Mitsushige Sugimoto, *Shiga*  
Masafumi Takahashi, *Tochigi*  
Shinji Takai, *Takatsuki*  
Yoh Takuwa, *Kanazawa*  
Shingo Tsuji, *Osaka*  
Hirokazu Tsukahara, *Fukui*  
Motoko Unoki, *Fukuoka*  
Shizuo Yamada, *Shizuoka*  
Norio Yasui-Furukori, *Hirosaki*  
Yukio Yoneda, *Kanazawa*



### Malaysia

Johnson Stanslas, *Serdang*



### Netherlands

Arjan Blokland, *Maastricht*  
Eliyahu Dremencov, *Groningen*  
Elisa Giovannetti, *Amsterdam*  
Hidde J Haisma, *Groningen*  
Frank A Redegeld, *Utrecht*  
Martina Schmidt, *Groningen*  
Frederik M van der Veen, *Rotterdam*  
Charles J Vecht, *The Hague*  
Joris C Verster, *Utrecht*



### New Zealand

Hesham Al-Sallami, *Dunedin*  
Lin Yang, *Dunedin*



### Poland

Thomas Brzozowski, *Cracow*  
Wladyslaw A Daniel, *Krakow*  
Andrzej Pilc, *Krakow*



### Portugal

Bruno Sarmento, *Porto*  
Cristina M Sena, *Coimbra*



### Russia

Roman G Efremov, *Moscow*



### Saint Kitts and Nevis

Ignacio Lizarraga, *Basseterre*



### Saudi Arabia

Mohamed AA Haidara, *Abha*



### Serbia

Milan Jokanovic, *Belgrade*



### Singapore

Jinsong Bian, *Singapore*  
Gavin S Dawe, *Singapore*  
Chang Ming Li, *Singapore*  
Haishu Lin, *Singapore*  
Rajkumar Ramamoorthy, *Singapore*  
Gautam Sethi, *Singapore*



### South Korea

Ki Churl Chang, *Jinju*  
Joohun Ha, *Seoul*  
Sang June Hahn, *Seoul*  
Byeongmoon Jeong, *Seoul*  
Myung Gull Lee, *Gyeonggi-Do*  
Won Suk Lee, *Gyeongsangnam-do*  
Seung-Yeol Nah, *Seoul*  
Kyoungso Suk, *Daegu*  
Young-Hyun Yoo, *Busan*



### Spain

José L Arias-Mediano, *Granada*  
Pedro E Bermejo, *Majadahonda*  
Fermin Sánchez de Medina LH, *Granada*  
Guillermo Elizondo, *Mexico City*  
Leandro Fernandez-Perez, *Las Palmas*  
Cristina Fillat, *Barcelona*  
J Adolfo Garcia-Sainz, *Mexico*  
Angel LM Gonzalez, *Salamanca*  
Tomas Herraiz, *Madrid*  
Miguel JA Lainez, *Valencia*  
Jose M Lanao, *Salamanca*  
ángel Lanas, *Zaragoza*  
Vicente Martinez, *Bellaterra*  
Faustino Mollinedo, *Salamanca*  
Virginia Motilva, *Sevilla*  
Gorka Orive, *Victoria*  
Ricardo E Perez-Tomas, *Barcelona*  
Susana Rodriguez-Couto, *Donostia-San Sebastian*  
Maria E Sáez, *Seville*  
Juan Sastre, *Valencia*  
Juan L Tamargo, *Madrid*  
Salvador V Zamora, *Barcelona*



### Sweden

Aleksander A Mathe, *Stockholm*  
Hari S Sharma, *Uppsala*  
Marie-Louise G Wadenberg, *Kalmar*  
Cang-Bao Xu, *Lund*



### Switzerland

Stefan J Borgwardt, *Basel*  
Felicien Karege, *Geneva*



### Thailand

Kanokwan Jarukamjorn, *Khon Kaen*



### Turkey

Cengiz A Akkaya, *Bursa*  
Fatih Canan, *Antalya*  
Saygin S Eker, *Bursa*  
Sule Apikoglu Rabus, *Istanbul*  
Nese Tuncel, *Eskisehir*  
Mehmet Yaman, *Elazig*



### United Kingdom

Sabine Bahn, *Cambridge*  
Christopher J Bushe, *New Malden*  
David J Chambers, *London*  
Rossen M Donev, *Swansea*  
Marco Falasca, *London*  
David J Grieve, *Belfast*  
Alan J Hargreaves, *Nottingham*  
Mahmoud M Iravani, *London*  
Nigel Irwin, *Coleraine*  
Lin-Hua Jiang, *Leeds*  
Veena Kumari, *London*  
Kim Lawson, *Sheffield*  
Debby MacMillan, *Glasgow*  
Elek Molnár, *Bristol*  
Stuart A Rushworth, *Norwich*  
Sunita Suri, *Nottingham*  
Jinsheng Xu, *Bristol*  
Alexander V Zholos, *Belfast*



### United States

James D Adams, *Los Angeles*  
Nihal Ahmad, *Madison*  
Gustav Akk, *St. Louis*  
Karim A Alkadhi, *Houston*  
Charles Antzelevitch, *Utica*  
Hugo R Arias, *Glendale*  
Dominick L Auci, *San Diego*  
Ross J Baldessarini, *Belmont*  
Oleg A Barski, *Louisville*  
Bjorn Bauer, *Duluth*  
Chengpeng Bi, *Kansas City*  
Karina S Blair, *Bethesda*  
Bortolato, Marco, *Los Angeles*  
Josh Burk, *Williamsburg*  
William K Chan, *Stockton*  
James J Chen, *Jefferson City*  
Zhe-Sheng Chen, *Queens*  
Beek Y Chin, *Boston*  
Olivier Civelli, *Irvine*  
John A Dani, *Houston*  
Keith M Erikson, *Greensboro*  
Eric R Fedyk, *Cambridge*  
Pingfu Feng, *Cleveland*  
William D Figg, *Bethesda*  
Mitchell P Fink, *Los Angeles*  
Masayuki Fukata, *Miami*  
Bolin Geng, *Waltham*  
Arup K Ghose, *West Chester*  
Alasdair M Gilfillan, *Bethesda*  
Neeraj Gupta, *Cambridge*

James P Hardwick, *Rootstown*  
David W Hein, *Louisville*  
Lawrence A Hill, *Salt Lake City*  
Huixiao Hong, *Jefferson*  
Andrew G Horti, *Baltimore*  
Eric Huang, *San Diego*  
Ying Huang, *Syracuse*  
Basalingappa L Hungund, *Orangeburg*  
Sally A Huston, *Athens*  
Kenneth A Jacobson, *Bethesda*  
Sabzali Javadov, *San Juan*  
Douglas L Jennings, *Detroit*  
Robert T Jensen, *Bethesda*  
Guang-Liang Jiang, *Irvine*  
Zhi-Gen Jiang, *Portland*  
Harish C Joshi, *Atlanta*  
Thomas H Kelly, *Lexington*  
Arifulla Khan, *Seattle*  
Mattheos Koffas, *Buffalo*  
Zbigniew K Krowicki, *New Orleans*  
Macus T Kuo, *Houston*  
Lorenzo Leggio, *Tehran*  
Jinhe Li, *Abbott Park*  
Liwu Li, *Blacksburg*  
Ching-Shwun Lin, *San Francisco*  
Yong Lin, *Albuquerque*  
Dongmin Liu, *Blacksburg*  
Jerry J Liu, *Kansas City*  
Ming-Cheh Liu, *Toledo*  
Xiu Liu, *Jackson*  
Edythe D London, *Los Angeles*  
Jian Lu, *Baltimore*  
Rudolf Lucas, *Augusta*  
Qing Ma, *Buffalo*

Iddo Magen, *Los Angeles*  
Gerald A Maguire, *Orange*  
Kenneth Maiese, *Newark*  
Stuart Maudsley, *Baltimore*  
Christopher R McCurdy, *Mississippi*  
Michael R McDevitt, *New York*  
Pamela A McKinley, *Detroit*  
Beverley Greenwood-Van Meerveld, *Oklahoma City*  
Kapil Mehta, *Houston*  
Murielle Mimeault, *Omaha*  
Ashim K Mitra, *Kansas City*  
Agostino Molteni, *Kansas City*  
Nader H Moniri, *Atlanta*  
Valentina E Moran, *Bay Pines*  
Sandeep Mukherjee, *Omaha*  
Oz Murat, *Baltimore*  
Masanori Onda, *Bethesda*  
Pal Pacher, *Rockville*  
Hui-Lin Pan, *Houston*  
Weihong Pan, *Baton Rouge*  
Giulio M Pasinetti, *New York*  
Kennerly S Patrick, *Charleston*  
George Perry, *San Antonio*  
James Porter, *Grand Forks*  
Lucas Pozzo-Miller, *Birmingham*  
Baskaran Rajasekaran, *Pittsburgh*  
Jeff Reagan, *Woodside*  
Victoria Risbrough, *San Diego*  
Michael A Rogawski, *Sacramento*  
Steven A Rosenzweig, *Charleston*  
Arnold E Ruoho, *Madison*  
Ahmad R Safa, *Indianapolis*  
Shakil A Saghir, *Midland*

Manar M Salem, *Columbus*  
Sanjeev Shangary, *Ann Arbor*  
Mahesh C Sharma, *Washington*  
Riyi Shi, *West Lafayette*  
Amruthesh C Shivachar, *Houston*  
Brij B Singh, *Grand Forks*  
Xue-Long Sun, *Cleveland*  
Manjunath N Swamy, *El Paso*  
Yvette Taché, *Los Angeles*  
Kevin S Thorneloe, *King of Prussia*  
Robin L Thurmond, *San Diego*  
Guochuan E Tsai, *Torrance*  
Tove Tuntland, *San Diego*  
Libor Velisek, *Valhalla*  
Christoph FA Vogel, *Davis*  
Christian Waeber, *Charlestown*  
Yu-Jui Y Wan, *Kansas City*  
Qin Wang, *Birmingham*  
R Clinton Webb, *Augusta*  
Thomas Wisniewski, *New York*  
Wing Tak Jack Wong, *Stanford*  
Jie Wu, *Phoenix*  
Zheng-Xiong Xi, *Baltimore*  
Da-Liao Xiao, *Loma Linda*  
Lixia Yao, *King of Prussia*  
Hao Yin, *Cambridge*  
Xiaozhong Yu, *Seattle*  
Chang-Guo Zhan, *Lexington*  
Hanting Zhang, *Morgantown*  
Qunwei Zhang, *Louisville*  
Shuxing Zhang, *Houston*  
Bao-Ting Zhu, *Kansas*  
Chang Z Zhu, *Abbott Park*



**MINIREVIEWS**

- 51 Long-term potentiation in autonomic ganglia: Potential role in cardiovascular disorders  
*Alkadhi KA*

## Contents

*World Journal of Pharmacology*  
Volume 5 Number 2 June 9, 2016

### ABOUT COVER

Editorial Board Number of *World Journal of Pharmacology*, Moses S Elisaf, FRSC, MD, Professor, Department of Internal Medicine, University of Ioannina, 45110 Ioannina, Greece

### AIM AND SCOPE

*World Journal of Pharmacology* (*World J Pharmacol*, *WJP*, online ISSN 2220-3192, DOI: 10.5497) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJP* covers topics concerning neuropsychiatric pharmacology, cerebrovascular pharmacology, geriatric pharmacology, anti-inflammatory and immunological pharmacology, antitumor pharmacology, anti-infective pharmacology, metabolic pharmacology, gastrointestinal and hepatic pharmacology, respiratory pharmacology, blood pharmacology, urinary and reproductive pharmacology, pharmacokinetics and pharmacodynamics, clinical pharmacology, and drug toxicology.

We encourage authors to submit their manuscripts to *WJP*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

### INDEXING/ABSTRACTING

*World Journal of Pharmacology* is currently no indexing/abstracting.

### FLYLEAF

#### I-IV Editorial Board

### EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Ya-Jing Lu*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Jin-Xin Kong*  
Proofing Editorial Office Director: *Xiu-Xia Song*

#### NAME OF JOURNAL

*World Journal of Pharmacology*

#### ISSN

ISSN 2220-3192 (online)

#### LAUNCH DATE

February 9, 2012

#### FREQUENCY

Quarterly

#### EDITOR-IN-CHIEF

Geoffrey Burnstock, PhD, DSc, FAA, FRCS (Hon), FRCP (Hon), FmedSci, FRS, Professor, Autonomic Neuroscience Centre, University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, United Kingdom

#### EDITORIAL OFFICE

Jin-Lei Wang, Director  
Xiu-Xia Song, Vice Director

#### *World Journal of Pharmacology*

Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: editorialoffice@wjgnet.com  
Help Desk: <http://www.wjgnet.com/esp/helpdesk.aspx>  
<http://www.wjgnet.com>

#### PUBLISHER

Baishideng Publishing Group Inc  
8226 Regency Drive,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: bpgoffice@wjgnet.com  
Help Desk: <http://www.wjgnet.com/esp/helpdesk.aspx>  
<http://www.wjgnet.com>

#### PUBLICATION DATE

June 9, 2016

#### COPYRIGHT

© 2016 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

#### SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

#### INSTRUCTIONS TO AUTHORS

Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

#### ONLINE SUBMISSION

<http://www.wjgnet.com/esp/>

## Long-term potentiation in autonomic ganglia: Potential role in cardiovascular disorders

Karim A Alkadhi

Karim A Alkadhi, Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204, United States

Author contributions: Alkadhi KA contributed all to this paper.

Conflict-of-interest statement: Alkadhi KA declares no conflict of interest related to this publication.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Karim A Alkadhi, PhD, Professor, Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, SR-2, Cullen Blvd, Houston, TX 77204, United States. [kalkadhi@uh.edu](mailto:kalkadhi@uh.edu)  
Telephone: +1-713-7431212  
Fax: +1-713-7431229

Received: April 22, 2016  
Peer-review started: April 28, 2016  
First decision: May 13, 2016  
Revised: May 21, 2016  
Accepted: May 27, 2016  
Article in press: June 2, 2016  
Published online: June 9, 2016

### Abstract

Ganglionic long-term potentiation (gLTP) is an activity-dependent, enduring enhancement of ganglionic transmission. This phenomenon may be induced in autonomic ganglia of an organism under certain conditions where

repetitive impulses surge from the central nervous system (CNS) to the periphery. Chronic stress, repetitive epileptic seizure or chronic use of CNS stimulants could induce gLTP, which would result in a long lasting heightening of sympathetic tone to the cardiovascular system causing hypertension and disturbed cardiac rhythm that may lead to sudden cardiac death. These conditions are briefly reviewed in this article.

**Key words:** Electrophysiology; Epilepsy; Ganglionic long-term potentiation; Sudden unexpected death in epilepsy; Central nervous system stimulants; Sudden cardiac death

© **The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Heightened activity of the central nervous system (CNS) caused by epilepsy, chronic stress and CNS stimulants could provide strong preganglionic stimulation of autonomic ganglia, which may trigger expression of ganglionic long-term potentiation (gLTP). Expression of gLTP can result in cardiovascular dysfunction that may lead to morbidity and even mortality.

Alkadhi KA. Long-term potentiation in autonomic ganglia: Potential role in cardiovascular disorders. *World J Pharmacol* 2016; 5(2): 51-58 Available from: URL: <http://www.wjgnet.com/2220-3192/full/v5/i2/51.htm> DOI: <http://dx.doi.org/10.5497/wjp.v5.i2.51>

### INTRODUCTION

Before Bliss and Lomo<sup>[1]</sup> coined the term "long-term potentiation (LTP)" in the hippocampus to describe activity-dependent long-lasting potentiation, similar activity-induced enhancement of synaptic transmission was described in the mammalian sympathetic ganglia<sup>[2,3]</sup>. However, it was nearly two decades before ganglionic LTP

**Table 1** Summary of studies reporting ganglionic long-term potentiation of the nicotinic pathway in various animal species

Animal species	Specific ganglia	Ref.
Rat	Superior cervical ganglion	Brown and McAfee <sup>[4]</sup>
		Briggs and McAfee <sup>[6]</sup>
		Alkadhi <i>et al</i> <sup>[15]</sup>
		Alzoubi <i>et al</i> <sup>[25]</sup>
		Alkadhi <i>et al</i> <sup>[28]</sup>
		Alkadhi <i>et al</i> <sup>[29]</sup>
Cat	Superior cervical, lumbar and stellate ganglia	Alkadhi and Alzoubi <sup>[36]</sup>
		Alzoubi <i>et al</i> <sup>[30]</sup>
		Alonso-deFlorida <i>et al</i> <sup>[7]</sup>
Guinea pig	Superior cervical ganglion	Bachoo and Polosa <sup>[8]</sup>
Chick	Parasympathetic ciliary ganglion	Weinreich <i>et al</i> <sup>[9]</sup>
Bullfrog	Sympathetic ganglia	Scott and Bennett <sup>[14]</sup>
		Koyano <i>et al</i> <sup>[11]</sup>
		Kumamoto and Kuba <sup>[13]</sup>
		Minota <i>et al</i> <sup>[10]</sup>

Adapted from Alkadhi K, Alzoubi K. In: Sudden Death in Epilepsy: Forensic and Clinical Issues (Chapter 26). CRC Press, 2011: 395-426.

(gLTP) was characterized in mammalian and amphibian sympathetic ganglia<sup>[4-13]</sup> as well as avian parasympathetic ciliary ganglion<sup>[14]</sup> (Table 1). Later, my laboratory identified serotonin as the neurotransmitter necessary for induction and maintenance of gLTP in the rat superior cervical ganglion<sup>[15]</sup>.

The expression of gLTP is due to a series of events resulting from both the postsynaptic and presynaptic regions, and including activation of enzymes, modulators and second messengers. Whereas LTP of the central nervous system (CNS) is regarded as a cellular mechanism of memory; the function of gLTP is uncertain. It is clear that hyperactivity of the CNS, as in the case of chronic stress or recurrent epileptic seizures, may provide the high frequency stimulation (HFS) necessary to induce the expression of LTP in autonomic ganglia, which may cause deleterious alterations in the cardiovascular system function.

gLTP is induced by repetitive HFS (20 Hz) of pre-ganglionic nerve. Upon cessation of HFS of the pre-ganglionic nerve of rat superior cervical ganglion, test stimuli (0.017 Hz) evoke initial highly potentiated ganglionic responses (compound action potentials), lasting up to 4 min, called post-tetanic potentiation<sup>[15-17]</sup>. This is followed by steady lesser-potentiated action potentials lasting up to 3 h, indicating an increase in synaptic strength<sup>[15,18-20]</sup>.

Published work from this laboratory determined that initiation of gLTP entails both HFS of the preganglionic nerve and stimulation of 5-HT<sub>3</sub> receptors by serotonin originating from certain cells within the superior cervical ganglion of rat<sup>[15]</sup>. Activation of 5-HT<sub>3</sub> receptors is necessary for both initiation and expression of gLTP<sup>[15]</sup>. Extracellular recording revealed that, in ganglia that have

**Table 2** Effects of various 5-HT<sub>3</sub> receptor agonists and antagonists on compound action potential during ganglionic long-term potentiation induced *in vitro* by high frequency repetitive stimulation

Serotonergic drugs	Mode of action	Compound AP
Serotonin (10-20 μmol/L)	Agonist	Increased
Fluoxetine (10 μmol/L)	SSRI	Increased
m-CPBG (1 μmol/L)	Receptor agonist	Increased
Tropisetron (5 μmol/L)	Receptor antagonist	Reduced
Ondansetron (5 μmol/L)	Receptor antagonist	Reduced
MDL 72222 (0.5 μmol/L)	Receptor antagonist	Reduced
Reserpine pretreatment (3 mg/kg)	5-HT <sub>3</sub> depletion	No gLTP
m-CPBG (1 μmol/L) + reserpine	Receptor agonist	Increased

The same drugs produced no significant effect on basal synaptic transmission in control ganglia (adapted from ref. [15,25,29,30,32,33,36]). SSRI: Selective serotonin reuptake inhibitor; AP: Action potential.


expressed gLTP, serotonin 5-HT<sub>3</sub> receptor agonists and blockers, in concentrations comparable to pharmacological doses in clinical settings, have profound effects on the magnitude of gLTP<sup>[15]</sup> (Table 2), even though the same agents produced no significant effect on basal transmission in ganglia from control rat<sup>[15]</sup>. Thus, we have established gLTP as the first serotonin-dependent LTP ever reported in a mammalian species<sup>[21,22]</sup>.

The 5-HT<sub>3</sub> receptor is a ligand-gated receptor-channel complex, and a member of the superfamily that also includes the nACh receptor<sup>[23]</sup>. It is known that activation of the presynaptic 5-HT<sub>3</sub> receptor causes upsurges in calcium concentration inside rat brain nerve terminals<sup>[24]</sup>. The role of 5-HT<sub>3</sub> receptor in the induction and maintenance of gLTP is presently unclear. Perhaps the activation of 5-HT<sub>3</sub> channel-receptor complex at the nerve terminals in ganglia causes localized entry of calcium ions increasing its intracellular concentration to a level adequate for activation of downstream signaling molecules, including protein kinase C (PKC), calmodulin and calcium-calmodulin kinase II (CaMK II), which are essential for expressing gLTP<sup>[25]</sup>.

## IN VITRO INDUCTION OF GLTP

gLTP can be induced by HFS (20 Hz for 20 s) of the pre-ganglionic sympathetic nerve. This frequency is within the maximum range of *in vivo* firing frequency of preganglionic neurons<sup>[26]</sup>. The response may be measured *in vitro* by intracellular or extracellular recording techniques<sup>[6]</sup>. Furthermore, gLTP has been evoked and recorded *in situ* from ganglia of anesthetized animals<sup>[7,8,27]</sup>.

The LTP of the hippocampal CA1 region and gLTP are similar in various aspects. For example, both are saturable in that when fully expressed, another HFS will not cause additional augmentation of synaptic trans-



**Figure 1** The hypothesis: In the whole animal, epileptic seizures provide the repetitive stimulation required for the expression of ganglionic long-term potentiation in sympathetic ganglia, resulting in increased peripheral resistance, hypertension and cardiopulmonary dysregulation leading to sudden death. Blocking serotonin 5-HT<sub>3</sub> receptor with antagonist (Zofran®) in ganglia has been shown to obviate the effect of gLTP. gLTP: Ganglionic long-term potentiation; CNS: Central nervous system; SUDEP: Sudden unexpected death in epilepsy.

mission<sup>[28]</sup>. Experiments in rat sympathetic ganglia suggest similar molecular mechanisms for the expression of gLTP and hippocampal LTP<sup>[29]</sup>. Both require a ligand-gated ion channel; here is where hippocampal LTP and gLTP differ: Whereas area CA1 hippocampal LTP requires activation of glutamate NMDA receptor, gLTP requires activation of serotonin 5-HT<sub>3</sub> receptor. Similar to NMDA receptor, 5-HT<sub>3</sub> receptor is very permeable to Ca<sup>2+</sup>, which is exceedingly important for launching the molecular cascades responsible for expression of LTP. Strong evidence from this laboratory reveals the involvement of a variety of signaling molecules (e.g., CaMK II, PKC, calmodulin, calcineurin, etc.) in the expression of both hippocampal LTP and gLTP<sup>[30,31]</sup>.

The involvement of endogenous serotonin is indicated by absence of HFS-induced gLTP in ganglia of animals treated with reserpine (3 mg/kg) to remove serotonin. However, when these ganglia were treated with serotonin or m-CPBG (a 5-HT<sub>3</sub>-receptor agonist), HFS invariably induced expression of gLTP (Table 2)<sup>[15]</sup>.


## IN VIVO EXPRESSION OF GLTP

An expected outcome from *in vivo* manifestation of gLTP in ganglia is a long-lasting enhancement of sympathetic tone that outflows to the cardiovascular system. Work from this laboratory has established the consequences of *in vivo* induction of gLTP in sympathetic ganglia on blood pressure<sup>[29,32,33]</sup>. We hypothesize that CNS repetitive activity causes similar outflow to preganglionic nerves, which together with endogenous serotonin may trigger expression of gLTP of sympathetic ganglia. Expression of gLTP produces prolonged and steady increase of

sympathetic tone to the cardiovascular resulting in hypertension and disturbed cardiac rhythm (Figure 1).

We hypothesized that chronic psychosocial stress can induce *in vivo* expression of gLTP in sympathetic ganglia, which results in a constant rise in sympathetic tone thus contributing to or initiating a rise of blood pressure. We tested this hypothesis in four animal models of hypertension; aged rats, spontaneously hypertensive rat (SHR), obese Zucker rat and the psychosocial stress model<sup>[28,33-35]</sup>. We investigated the existence of gLTP in ganglia from these models. For example, in psychosocially stressed hypertensive rats, treatment with tropisetron (ICS; a 5-HT<sub>3</sub> receptor antagonist) resulted in normalizing blood pressure of these rats (Figure 2; ref. [29]). Parallel outcomes were obtained in SHR and obese Zucker rat<sup>[29,32]</sup>. This strongly indicated that the hypertension seen in these animals was, at least partly, due to expression of gLTP.

To further ascertain the existence of gLTP in ganglia isolated from these animal models we showed that "basal" transmission in these ganglia was markedly potentiated (Figure 3A) and that this potentiation was blocked when ganglia were treated with 5-HT<sub>3</sub> receptor antagonists<sup>[29,32,33,35]</sup> (Figure 3B). In another series of experiments, we hypothesized that *in vitro* HFS will not induce gLTP in ganglia isolated from hypertensive old rats if, in fact, gLTP has been expressed already in these ganglia *in vivo*. Whereas HFS produced strong gLTP in ganglia isolated from normotensive adult rats, no gLTP was seen in ganglia from old rats<sup>[28,35]</sup> (Figure 3C). It is worthy to note that in these series, to ascertain the specificity of 5-HT<sub>3</sub> receptor we used three different selective antagonists; bemisetron, tropisetron and ondansetron (Zo-



**Figure 2** Tropisetron (ICS) normalizes established stress hypertension in psychosocially stressed male rats without affecting blood pressure in control (unstressed) rats measured at day 30 of continuous stress. Blood pressure was measured by tail-cuff plethysmography. Similar results were obtained from female rats. Each point in each group is the mean  $\pm$  SD from 5 male or female rats. (a) indicates significant difference from other groups (Adapted from ref. [29]).

fran), all were equally effective in blocking gLTP<sup>[28,33-35]</sup>.

## POTENTIAL INDUCTION OF GLTP IN BRAIN ILLNESSES AND BY DRUGS

Any procedure that can induce continuous intense flow of impulses from the brain to autonomic ganglia could cause a sustained increase of sympathetic tone to the cardiovascular system, may lead to or contribute to disorders of the system<sup>[28-30,32,33,36]</sup> (Figure 1). The expression of gLTP in autonomic ganglia that may cause hypertension and cardiac arrhythmias can be a serious risk factor for morbidity and mortality. Evidence that associates expression of gLTP with hypertension has been determined for chronic psychosocial stress<sup>[28-30,32,33,36]</sup>. Other possible inducers of gLTP are discussed in the following sections.

## POSTTRAUMATIC STRESS DISORDER

This serious type of stress results from experiencing harsh distressing occurrences for example witnessing injuries or death, exposure to natural disasters, or experiencing a life-threatening accident. Posttraumatic stress disorder (PTSD) is an incapacitating and potentially chronic disorder characterized by substantial illness. Although similar in some features to chronic stress, PTSD has distinctive pathology<sup>[37]</sup>. In the first few years following the traumatic event, some PTSD patients may recover, but up to 40% remain chronically symptomatic for years<sup>[38]</sup>. The major brain areas implicated in the manifestation of PTSD are the prefrontal cortex, amygdala, and hippocampus<sup>[39]</sup>. During a traumatic event the amygdala sends intensifying impulses to various areas of the brain including prefrontal cortex, hypothalamus, hippocampus and brain stem nuclei. During the course of PTSD, intensified brain activity has been described. For example, PTSD patients showed

augmented spontaneous activity in the amygdala and frontal cortex<sup>[40]</sup>. Moreover, PTSD is linked to increased sympathetic activity represented by elevated blood pressure increased heart rate, and/or increased adrenergic transmitter release<sup>[41]</sup>. This increase in sympathetic activity could be due to expression of gLTP in autonomic ganglia. However, whether gLTP is present in ganglia during the progression of PTSD and whether cardiovascular disorders are due to gLTP in autonomic ganglia remain to be explored in animal models of PTSD.

## EPILEPSY


The excessive and abnormal cortical brain activity in epilepsy is transmitted through the brain stem to the rest of the body and can usually cause various types of seizures. Strong stimulation of the sympathetic nervous system often accompany seizures and can cause hypertension, dispersed injury of myocytes, and increased predisposition to ventricular arrhythmias<sup>[42,43]</sup>. Several areas in the brain are involved in the cardiovascular effect of epileptic seizures such as the hypothalamus and medulla oblongata, particularly nuclei of the nucleus tractus solitarius, and area postrema, which are closely engaged in regulation of cardiovascular function<sup>[44-46]</sup>. Therefore, enhanced activity of these areas is communicated to autonomic ganglia and may provide the required repetitive activity that triggers the expression of gLTP in these ganglia. The expression of gLTP results in long-term enhancement of sympathetic tone to the cardiovascular system, causing hypertension and neurogenic cardiac arrhythmias, which can be major risk factors for sudden unexpected death in epilepsy, a dangerous clinical difficulty for certain epileptic patients, especially those with chronic, inadequately controlled seizures.

## NICOTINE

Epileptiform brain activity was recorded in the brains of young rats treated with nicotine<sup>[47]</sup>. In humans, chronic use of tobacco products is known to cause enhanced cholinergic activity in the brain<sup>[48-50]</sup>. Nicotine can also augment peripheral sympathetic activity through activation of postganglionic nicotinic acetylcholine receptors<sup>[51,52]</sup>. Moreover, nicotine can release epinephrine from the adrenal medulla into the blood<sup>[53,54]</sup>. Thus, nicotine causes stimulation of the cardiovascular system that increases heart rate and causes hypertension by action on both peripheral and central sites<sup>[53]</sup>. Hence, since epileptic patients are more likely to be chronic tobacco users<sup>[55]</sup>, such chronic use of nicotine may result in the expression of gLTP in ganglia or enhancement of the impacts of already expressed gLTP in epileptic tobacco users, thus intensify the risk for cardiovascular dysfunction that may cause sudden death<sup>[56]</sup>.

## CAFFEINE

Caffeine, a competitive inhibitor of adenosine receptors,



**Figure 3** Expression of ganglionic long-term potentiation in sympathetic superior cervical ganglia in aged (22 mo) hypertensive rats. A: Input/output curve (I/O) of aged animal ganglia compared to adult (6 mo) ganglia, indicating enhanced synaptic activity in the aged animal ganglia. Stimulus intensity numbers along the X-axis are arbitrary values, where 1 is the minimal and 8 the maximal response (CAP amplitude in mV). Each point from aged rats is significantly different from matching points of adult rats, and is the mean  $\pm$  SEM from 5-7 ganglia; B: Inhibition of "baseline" ganglionic transmission in aged rats by a 5-HT<sub>3</sub> receptor antagonist ondansetron (Zofran) as an indication of expression of gLTP *in vivo*. Zofran (0.5  $\mu$ mol/L, solid horizontal line) decreased CAP baseline of ganglia isolated from aged but not of those isolated from adult rats. All points between the two "a" are significantly different ( $P < 0.05$ ) from corresponding point for adult rats. Each point in each series is the mean  $\pm$  SEM from 5-7 ganglia. Inset: CAPs of aged rats before and after application of drug; calibration 0.5 mV/20 ms; C: High frequency stimulation (HFS: 20 Hz/20 s, at 0 time) of the preganglionic nerves evoked robust gLTP in ganglia excised from adult rats. Identical protocol in ganglia from aged rats produced no gLTP. Each point represents the mean  $\pm$  SEM from 5 ganglia. Adapted from ref. [35]. gLTP: Ganglionic long-term potentiation; CAP: Compound action potential.

is the most extensively used CNS stimulant because it is consumed in a variety of hot and cold drinks, as well as many prescription and over-the-counter medications. Neuroimaging studies reports show that by acting on brain cortex, caffeine enhances attention and mental arousal<sup>[57-59]</sup>. However, there is no convincing evidence that the usual doses of caffeine increase the risk of heart attack, sudden cardiac death, or disruption of cardiac rhythm. Nonetheless, a new caffeine source are the so called "energy drinks", which contain uncommonly hefty doses of caffeine. Consumption of such energy drinks may lead to platelet and endothelial dysfunction, which can cause myocardial infarction and other cardiovascular disorders in healthy young adults<sup>[60-62]</sup> (for review see ref. [63]). Through stimulation of the CNS, heavy frequent intake of caffeine-containing drinks may trigger gLTP in sympathetic ganglia, which could be responsible for the reported cardiovascular disturbances. The danger may be even greater when such consumption of large doses

of caffeine is coupled with heavy use of tobacco products.

## AMPHETAMINES AND COCAINE

The amphetamines work mainly by modifying the catecholamine system in the pleasure center of the brain<sup>[64]</sup>. They increase levels of major catecholamines such as dopamine and norepinephrine in a dose-dependent manner<sup>[65-67]</sup>. A case-control study has linked the use of one of the most commonly used CNS stimulant, methylphenidate (Ritalin), to sudden death in children and teenagers<sup>[68]</sup>.

Cocaine inhibits the monoamine reuptake mechanism in central and peripheral sympathetic nerve terminals in humans<sup>[69-71]</sup> with end effects similar to those seen with amphetamines. This however, may not be the sole CNS effect of cocaine inasmuch as other reuptake inhibitors do not have cocaine-like effects. The abuse of cocaine is correlated with cardiovascular dysfunction including hypertension, ventricular dysrhythmia, acute myocardial

infarction, and left ventricular hypertrophy. Therefore, the chronic use of CNS stimulants such as amphetamine and cocaine may trigger expression of gLTP, which may lead to morbidity and/or sudden death.

## CONCLUSION

Abnormal strong brain activity as in epileptic seizures cause intense activation of ganglionic neurons, which can induce gLTP in sympathetic ganglia leading to long-term heightened sympathetic tone to the cardiovascular system with the ensuing rise in blood pressure and disturbed heart rhythm. Abnormal CNS activity can result from severe brain injuries, ongoing psychological stress, epilepsy, and regular abuse of CNS stimulating substances. Even though these disorders can cause disturbances of the function of the cardiovascular system, their possible link to gLTP has not been studied, except in chronic psychosocial stress. Therefore, it is necessary to determine such links in order to develop therapeutic plans to avoid serious consequences such as sudden cardiac death.

## REFERENCES

- 1 **Bliss TV**, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. *J Physiol* 1973; **232**: 331-356 [PMID: 4727084 DOI: 10.1113/jphysiol.1973.sp010273]
- 2 **Volle RL**. Enhancement of neuromuscular responses to acetylcholine and succinylcholine following repetitive stimulation of the motor nerve. *Arch Int Pharmacodyn Ther* 1966; **160**: 284-293 [PMID: 5954031]
- 3 **Dunant Y**, Dolivo M. Plasticity of synaptic functions in the excised sympathetic ganglion of the rat. *Brain Res* 1968; **10**: 271-273 [PMID: 5683552 DOI: 10.1016/0006-8993(68)90134-0]
- 4 **Brown TH**, McAfee DA. Long-term synaptic potentiation in the superior cervical ganglion. *Science* 1982; **215**: 1411-1413 [PMID: 6278593 DOI: 10.1126/science.6278593]
- 5 **Briggs CA**, McAfee DA, McCaman RE. Long-term potentiation of synaptic acetylcholine release in the superior cervical ganglion of the rat. *J Physiol* 1985; **363**: 181-190 [PMID: 2991505 DOI: 10.1113/jphysiol.1985.sp015703]
- 6 **Briggs CA**, McAfee DA. Long-term potentiation at nicotinic synapses in the rat superior cervical ganglion. *J Physiol* 1988; **404**: 129-144 [PMID: 2855347 DOI: 10.1113/jphysiol.1988.sp017282]
- 7 **Alonso-deFlorida F**, Morales MA, Minzoni AA. Modulated long-term potentiation in the cat superior cervical ganglion in vivo. *Brain Res* 1991; **544**: 203-210 [PMID: 2039938 DOI: 10.1016/0006-8993(91)90055-Z]
- 8 **Bachoo M**, Polosa C. Preganglionic axons from the third thoracic spinal segment fail to induce long-term potentiation in the superior cervical ganglion of the cat. *Can J Physiol Pharmacol* 1992; **70** Suppl: S27-S31 [PMID: 1338296 DOI: 10.1139/y92-240]
- 9 **Weinreich D**, Udem BJ, Taylor G, Barry MF. Antigen-induced long-term potentiation of nicotinic synaptic transmission in the superior cervical ganglion of the guinea pig. *J Neurophysiol* 1995; **73**: 2004-2016 [PMID: 7623097]
- 10 **Minota S**, Kumamoto E, Kitakoga O, Kuba K. Long-term potentiation induced by a sustained rise in the intracellular  $Ca^{2+}$  in bull-frog sympathetic ganglia. *J Physiol* 1991; **435**: 421-438 [PMID: 1685189 DOI: 10.1113/jphysiol.1991.sp018517]
- 11 **Koyano K**, Kuba K, Minota S. Long-term potentiation of transmitter release induced by repetitive presynaptic activities in bull-frog sympathetic ganglia. *J Physiol* 1985; **359**: 219-233 [PMID: 2860240 DOI: 10.1113/jphysiol.1985.sp015582]
- 12 **Kumamoto E**, Kuba K. Sustained rise in ACh sensitivity of a sympathetic ganglion cell induced by postsynaptic electrical activities. *Nature* 1983; **305**: 145-146 [PMID: 6604228 DOI: 10.1038/305145a0]
- 13 **Kumamoto E**, Kuba K. Mechanism of long-term potentiation of transmitter release induced by adrenaline in bullfrog sympathetic ganglia. *J Gen Physiol* 1986; **87**: 775-793 [PMID: 2873199 DOI: 10.1085/jgp.87.5.775]
- 14 **Scott TR**, Bennett MR. The effect of ions and second messengers on long-term potentiation of chemical transmission in avian ciliary ganglia. *Br J Pharmacol* 1993; **110**: 461-469 [PMID: 8220908 DOI: 10.1111/j.1476-5381.1993.tb13833.x]
- 15 **Alkadhi KA**, Salgado-Commissariat D, Hogan YH, Akpaudo SB. Induction and maintenance of ganglionic long-term potentiation require activation of 5-hydroxytryptamine (5-HT<sub>3</sub>) receptors. *J Physiol* 1996; **496** (Pt 2): 479-489 [PMID: 8910231 DOI: 10.1113/jphysiol.1996.sp021700]
- 16 **Martin AR**, Pilar G. Presynaptic and post-synaptic events during post-tetanic potentiation and facilitation in the avian ciliary ganglion. *J Physiol* 1964; **175**: 17-30 [PMID: 1424155 DOI: 10.1113/jphysiol.1964.sp007500]
- 17 **Magleby KL**, Zengel JE. A quantitative description of tetanic and post-tetanic potentiation of transmitter release at the frog neuromuscular junction. *J Physiol* 1975; **245**: 183-208 [PMID: 165286 DOI: 10.1113/jphysiol.1975.sp010840]
- 18 **Bennett MR**. Nitric oxide release and long term potentiation at synapses in autonomic ganglia. *Gen Pharmacol* 1994; **25**: 1541-1551 [PMID: 7721027 DOI: 10.1016/0306-3623(94)90353-0]
- 19 **Brain KL**, Bennett MR. Calcium in the nerve terminals of chick ciliary ganglia during facilitation, augmentation and potentiation. *J Physiol* 1995; **489** (Pt 3): 637-648 [PMID: 8788930 DOI: 10.1113/jphysiol.1995.sp021079]
- 20 **Lin YQ**, Bennett MR. Nitric oxide modulation of quantal secretion in chick ciliary ganglia. *J Physiol* 1994; **481** (Pt 2): 385-394 [PMID: 7537816 DOI: 10.1113/jphysiol.1994.sp020447]
- 21 **Madison DV**, Schuman EM. LTP, post or pre? A look at the evidence for the locus of long-term potentiation. *New Biol* 1991; **3**: 549-557 [PMID: 1680385]
- 22 **Johnston D**, Williams S, Jaffe D, Gray R. NMDA-receptor-independent long-term potentiation. *Annu Rev Physiol* 1992; **54**: 489-505 [PMID: 1314043 DOI: 10.1146/annurev.ph.54.030192.002421]
- 23 **Derkach V**, Surprenant A, North RA. 5-HT<sub>3</sub> receptors are membrane ion channels. *Nature* 1989; **339**: 706-709 [PMID: 2472553 DOI: 10.1038/339706a0]
- 24 **Nichols RA**, Mollard P. Direct observation of serotonin 5-HT<sub>3</sub> receptor-induced increases in calcium levels in individual brain nerve terminals. *J Neurochem* 1996; **67**: 581-592 [PMID: 8764583 DOI: 10.1046/j.1471-4159.1996.67020581.x]
- 25 **Alzoubi KH**, Bedawi AS, Aleisa AM, Alkadhi KA. Hypothyroidism impairs long-term potentiation in sympathetic ganglia: electrophysiologic and molecular studies. *J Neurosci Res* 2004; **78**: 393-402 [PMID: 15389831 DOI: 10.1002/jnr.20268]
- 26 **Coote JH**, Westbury DR. Intracellular recordings from sympathetic preganglionic neurones. *Neurosci Lett* 1979; **15**: 171-175 [PMID: 530526 DOI: 10.1016/0304-3940(79)96108-1]
- 27 **Bachoo M**, Heppner T, Fiekers J, Polosa C. A role for protein kinase C in long term potentiation of nicotinic transmission in the superior cervical ganglion of the rat. *Brain Res* 1992; **585**: 299-302 [PMID: 1324771 DOI: 10.1016/0006-8993(92)91223-2]
- 28 **Alkadhi KA**, Alzoubi KH, Aleisa AM, Tanner FL, Nimer AS. Psychosocial stress-induced hypertension results from in vivo expression of long-term potentiation in rat sympathetic ganglia. *Neurobiol Dis* 2005; **20**: 849-857 [PMID: 16005635 DOI: 10.1016/j.nbd.2005.05.020]
- 29 **Alkadhi KA**, Alzoubi KH, Aleisa AM. Plasticity of synaptic transmission in autonomic ganglia. *Prog Neurobiol* 2005; **75**: 83-108 [PMID: 15784301 DOI: 10.1016/j.pneurobio.2005.02.002]
- 30 **Alzoubi KH**, Aleisa AM, Alkadhi KA. Expression of gLTP in sympathetic ganglia of obese Zucker rats in vivo: molecular evidence. *J Mol Neurosci* 2008; **35**: 297-306 [PMID: 18563301 DOI: 10.1007/s12031-008-9110-6]
- 31 **Gerges NZ**, Alzoubi KH, Alkadhi KA. Role of phosphorylated

- CaMKII and calcineurin in the differential effect of hypothyroidism on LTP of CA1 and dentate gyrus. *Hippocampus* 2005; **15**: 480-490 [PMID: 15714506 DOI: 10.1002/hipo.20073]
- 32 **Gerges NZ**, Aleisa AM, Alhaider AA, Alkadhi KA. Reduction of elevated arterial blood pressure in obese Zucker rats by inhibition of ganglionic long-term potentiation. *Neuropharmacology* 2002; **43**: 1070-1076 [PMID: 12504912 DOI: 10.1016/S0028-3908(02)00283-6]
  - 33 **Alkadhi KA**, Ootom SA, Tanner FL, Sockwell D, Hogan YH. Inhibition of ganglionic long-term potentiation decreases blood pressure in spontaneously hypertensive rats. *Exp Biol Med* (Maywood) 2001; **226**: 1024-1030 [PMID: 11743138]
  - 34 **Gerges NZ**, Aleisa AM, Schwarz LA, Alkadhi KA. Chronic psychosocial stress decreases calcineurin in the dentate gyrus: a possible mechanism for preservation of early ltp. *Neuroscience* 2003; **117**: 869-874 [PMID: 12654339 DOI: 10.1016/S0306-4522(02)00766-2]
  - 35 **Alzoubi KH**, Aleisa AM, Alkadhi KA. In vivo expression of ganglionic long-term potentiation in superior cervical ganglia from hypertensive aged rats. *Neurobiol Aging* 2010; **31**: 805-812 [PMID: 18649973 DOI: 10.1016/j.neurobiolaging.2008.06.007]
  - 36 **Alkadhi K**, Alzoubi K. Role of long-term potentiation of sympathetic ganglia (gLTP) in hypertension. *Clin Exp Hypertens* 2007; **29**: 267-286 [PMID: 17653963 DOI: 10.1080/10641960701500356]
  - 37 **Vieweg WV**, Julius DA, Fernandez A, Beatty-Brooks M, Hettema JM, Pandurangi AK. Posttraumatic stress disorder: clinical features, pathophysiology, and treatment. *Am J Med* 2006; **119**: 383-390 [PMID: 16651048 DOI: 10.1016/j.amjmed.2005.09.027]
  - 38 **Kessler RC**, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. *Arch Gen Psychiatry* 1995; **52**: 1048-1060 [PMID: 7492257 DOI: 10.1001/archpsyc.1995.03950240066012]
  - 39 **Brunello N**, Davidson JR, Deahl M, Kessler RC, Mendlewicz J, Racagni G, Shalev AY, Zohar J. Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. *Neuropsychobiology* 2001; **43**: 150-162 [PMID: 11287794]
  - 40 **Yan X**, Brown AD, Lazar M, Cressman VL, Henn-Haase C, Neylan TC, Shalev A, Wolkowitz OM, Hamilton SP, Yehuda R, Sodickson DK, Weiner MW, Marmar CR. Spontaneous brain activity in combat related PTSD. *Neurosci Lett* 2013; **547**: 1-5 [PMID: 23643995 DOI: 10.1016/j.neulet.2013.04.032]
  - 41 **Morris MC**, Rao U. Psychobiology of PTSD in the acute aftermath of trauma: Integrating research on coping, HPA function and sympathetic nervous system activity. *Asian J Psychiatr* 2013; **6**: 3-21 [PMID: 23380312 DOI: 10.1016/j.ajp.2012.07.012]
  - 42 **Ishiguro Y**, Morgan JP. Effect of endogenous catecholamine on myocardial stunning in a simulated ischemia model. *Fundam Clin Pharmacol* 2001; **15**: 111-116 [PMID: 11468020]
  - 43 **Shimizu M**, Kagawa A, Takano T, Masai H, Miwa Y. Neurogenic stunned myocardium associated with status epilepticus and postictal catecholamine surge. *Intern Med* 2008; **47**: 269-273 [PMID: 18277028]
  - 44 **Colice GL**. Neurogenic pulmonary edema. *Clin Chest Med* 1985; **6**: 473-489 [PMID: 3907948]
  - 45 **Stauffer AZ**, Dodd-o J, Lathers CM. The relationship of the lock-step phenomenon and precipitous changes in mean arterial blood pressure. *Electroencephalogr Clin Neurophysiol* 1989; **72**: 340-345 [PMID: 2467800 DOI: 10.1016/0013-4694(89)90070-9]
  - 46 **Davison DL**, Terek M, Chawla LS. Neurogenic pulmonary edema. *Crit Care* 2012; **16**: 212 [PMID: 22429697 DOI: 10.1186/cc11226]
  - 47 **Hralová M**, Marešová D, Riljak V. Effect of the single-dose of nicotine-administration on the brain bioelectrical activity and on behaviour in immature 12-day-old rats. *Prague Med Rep* 2010; **111**: 182-190 [PMID: 20946718]
  - 48 **Rose JE**, Behm FM, Salley AN, Bates JE, Coleman RE, Hawk TC, Turkington TG. Regional brain activity correlates of nicotine dependence. *Neuropsychopharmacology* 2007; **32**: 2441-2452 [PMID: 17356570 DOI: 10.1038/sj.npp.1301379]
  - 49 **Gloria R**, Angelos L, Schaefer HS, Davis JM, Majeskie M, Richmond BS, Curtin JJ, Davidson RJ, Baker TB. An fMRI investigation of the impact of withdrawal on regional brain activity during nicotine anticipation. *Psychophysiology* 2009; **46**: 681-693 [PMID: 19490513 DOI: 10.1111/j.1469-8986.2009.00823.x]
  - 50 **Beaver JD**, Long CJ, Cole DM, Durcan MJ, Bannon LC, Mishra RG, Matthews PM. The effects of nicotine replacement on cognitive brain activity during smoking withdrawal studied with simultaneous fMRI/EEG. *Neuropsychopharmacology* 2011; **36**: 1792-1800 [PMID: 21544072 DOI: 10.1038/npp.2011.53]
  - 51 **Haass M**, Kübler W. Nicotine and sympathetic neurotransmission. *Cardiovasc Drugs Ther* 1997; **10**: 657-665 [PMID: 9110108 DOI: 10.1007/BF00053022]
  - 52 **Adamopoulos D**, van de Borne P, Argacha JF. New insights into the sympathetic, endothelial and coronary effects of nicotine. *Clin Exp Pharmacol Physiol* 2008; **35**: 458-463 [PMID: 18307741 DOI: 10.1111/j.1440-1681.2008.04896.x]
  - 53 **Hill P**, Wynder EL. Smoking and cardiovascular disease. Effect of nicotine on the serum epinephrine and corticoids. *Am Heart J* 1974; **87**: 491-496 [PMID: 4817106 DOI: 10.1016/0002-8703(74)90174-4]
  - 54 **Grunberg NE**, Popp KA, Bowen DJ, Nespor SM, Winders SE, Eury SE. Effects of chronic nicotine administration on insulin, glucose, epinephrine, and norepinephrine. *Life Sci* 1988; **42**: 161-170 [PMID: 3275854 DOI: 10.1016/0024-3205(88)90679-0]
  - 55 **Ferguson PL**, Chiprich J, Smith G, Dong B, Wannamaker BB, Kobau R, Thurman DJ, Selassie AW. Prevalence of self-reported epilepsy, health care access, and health behaviors among adults in South Carolina. *Epilepsy Behav* 2008; **13**: 529-534 [PMID: 18585962 DOI: 10.1016/j.yebeh.2008.05.005]
  - 56 **Rong L**, Frontera AT, Benbadis SR. Tobacco smoking, epilepsy, and seizures. *Epilepsy Behav* 2014; **31**: 210-218 [PMID: 24441294 DOI: 10.1016/j.yebeh.2013.11.022]
  - 57 **Koppelstaetter F**, Poeppel TD, Siedentopf CM, Ischebeck A, Kolbitsch C, Mottaghy FM, Felber SR, Jaschke WR, Krause BJ. Caffeine and cognition in functional magnetic resonance imaging. *J Alzheimers Dis* 2010; **20** Suppl 1: S71-S84 [PMID: 20182040]
  - 58 **Koppelstaetter F**, Poeppel TD, Siedentopf CM, Ischebeck A, Verius M, Haala I, Mottaghy FM, Rhomberg P, Golaszewski S, Gotwald T, Lorenz IH, Kolbitsch C, Felber S, Krause BJ. Does caffeine modulate verbal working memory processes? An fMRI study. *Neuroimage* 2008; **39**: 492-499 [PMID: 17936643 DOI: 10.1016/j.neuroimage.2007.08.037]
  - 59 **Park CA**, Kang CK, Son YD, Choi EJ, Kim SH, Oh ST, Kim YB, Park CW, Cho ZH. The effects of caffeine ingestion on cortical areas: functional imaging study. *Magn Reson Imaging* 2014; **32**: 366-371 [PMID: 24512799 DOI: 10.1016/j.mri.2013.12.018]
  - 60 **Worthley MI**, Prabhu A, De Sciscio P, Schultz C, Sanders P, Willoughby SR. Detrimental effects of energy drink consumption on platelet and endothelial function. *Am J Med* 2010; **123**: 184-187 [PMID: 20103032 DOI: 10.1016/j.amjmed.2009.09.013]
  - 61 **Thyagarajan B**, Alagusundaramoorthy SS, Agrawal A. Atrial Fibrillation Due to Over The Counter Stimulant Drugs in A Young Adult. *J Clin Diagn Res* 2015; **9**: OD05-OD07 [PMID: 26435989 DOI: 10.7860/jcdr/2015/13483.6330]
  - 62 **Ibrahim NK**, Ifikhar R. Energy drinks: Getting wings but at what health cost? *Pak J Med Sci* 2014; **30**: 1415-1419 [PMID: 25674149 DOI: 10.12669/pjms.306.5396]
  - 63 **Lippi G**, Cervellin G, Sanchis-Gomar F. Energy Drinks and Myocardial Ischemia: A Review of Case Reports. *Cardiovasc Toxicol* 2016; **16**: 207-212 [PMID: 26320007 DOI: 10.1007/s12012-015-9339-6]
  - 64 **Bidwell LC**, McClernon FJ, Kollins SH. Cognitive enhancers for the treatment of ADHD. *Pharmacol Biochem Behav* 2011; **99**: 262-274 [PMID: 21596055 DOI: 10.1016/j.pbb.2011.05.002]
  - 65 **Miller GM**. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. *J Neurochem* 2011; **116**: 164-176 [PMID: 21073468 DOI: 10.1111/j.1471-4159.2010.07109.x]
  - 66 **Mikkelsen E**, Lake CR, Brown GL, Ziegler MG, Ebert MH. The hyperactive child syndrome: peripheral sympathetic nervous system function and the effect of d-amphetamine. *Psychiatry Res* 1981; **4**: 157-169 [PMID: 6939007 DOI: 10.1016/0165-1781(81)90019-6]
  - 67 **Eiden LE**, Weihe E. VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. *Ann N Y Acad Sci* 2011; **1216**: 86-98 [PMID: 21272013 DOI: 10.1111/

j.1749-6632.2010.05906.x]

- 68 **Gould MS**, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T. Sudden death and use of stimulant medications in youths. *Am J Psychiatry* 2009; **166**: 992-1001 [PMID: 19528194 DOI: 10.1176/appi.ajp.2009.09040472]
- 69 **Melon PG**, Boyd CJ, McVey S, Mangner TJ, Wieland DM, Schwaiger M. Effects of active chronic cocaine use on cardiac sympathetic neuronal function assessed by carbon-11-hydroxyephedrine. *J Nucl Med* 1997; **38**: 451-456 [PMID: 9074537]
- 70 **Vongpatanasin W**, Mansour Y, Chavoshan B, Arbique D, Victor RG. Cocaine stimulates the human cardiovascular system via a central mechanism of action. *Circulation* 1999; **100**: 497-502 [PMID: 10430763 DOI: 10.1161/01.CIR.100.5.497]
- 71 **Lange RA**, Hillis LD. Cardiovascular complications of cocaine use. *N Engl J Med* 2001; **345**: 351-358 [PMID: 11484693 DOI: 10.1056/NEJM200108023450507]

**P- Reviewer:** Takahashi H, Unger M **S- Editor:** Gong XM  
**L- Editor:** A **E- Editor:** Lu YJ





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

